Drug maker AstraZeneca Pharma India Ltd (APIL) board has approved to invest Rs 70 crore to expand tablet manufacturing capacity. Ordinarily, the size of the investment would warrant little attention. But it becomes significant for a few reasons.
Emerging markets are expected to contribute around 70% of the drugs market growth between 2009 and 2014. AstraZeneca Plc strategy is to grow its presence in the so-called Brazil, Russia, India, China, Mexico and Turkey markets, grow its involvement in smaller but high-growth markets and include branded generics in its portfolio. The expansion seems to part of APIL’s growth plans in
AstraZeneca’s presence in
This and its capital expenditure plans, too, will put some pressure on its near term profitability. Eventually, as its product pipeline ramps up, both sales and profit growth will rise at a much faster rate, resulting in a better financial performance.
crackcrackCompany Name | CMP |
---|---|
Sun Pharma Inds. | 1770.50 |
Dr. Reddys Lab | 1203.00 |
Cipla | 1475.95 |
Lupin | 2053.90 |
Zydus Lifesciences | 942.25 |
View more.. |